Abiraterone - What is wrong with the adrenal glands?

Clinical Genitourinary Cancer

Volumn 12, Issue 4, 2014, Pages

  Schmid, Sabine ^a   Fornaro, Jürgen ^b   Rothermundt, Christian ^a   Omlin, Aurelius ^a   Brändle, Michael ^b   Rupp, Niels J ^b   Gillessen, Silke ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b Department of Radiology Kantonsspital St Gallen ^*  (Switzerland)

Author keywords

Abiraterone acetate; Adrenal gland metastases; Metastatic castration resistant prostate cancer; Steroid switch; Visceral disease

Indexed keywords

ABIRATERONE ACETATE; DEXAMETHASONE; DOCETAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ABIRATERONE; ANDROSTANE DERIVATIVE; ANTIANDROGEN;

ADRENAL METASTASIS; ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CASE REPORT; CASTRATION RESISTANT PROSTATE CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; GENERAL CONDITION DETERIORATION; HUMAN; HYPERTROPHY; MALE; MIDDLE AGED; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE; TREATMENT DURATION; ADRENAL GLAND NEOPLASMS; CHEMICALLY INDUCED; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY;

ADRENAL GLAND NEOPLASMS; ANDROGEN ANTAGONISTS; ANDROSTENES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84904679491     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.01.008     Document Type: Article

References (17)

1. H.I. Scher, S. Halabi, and I. Tannock et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
2. N.R. Dunnick, and M. Korobkin Imaging of adrenal incidentalomas: current status AJR Am J Roentgenol 179 2002 559 568
3. Lorente D, Weatherstone K, Omlin A, et al. Tumor responses after steroid switch of prednisolone (P) to dexamethasone (D) in castration-resistant prostate cancer (CRPC) patients (pts) on abiraterone acetate (AA) (abstract 2918). Presented at the European Cancer Conference; September 27-October 1, 2013; Amsterdam, Netherlands.
4. G. Mansmann, J. Lau, and E. Balk et al. The clinically inapparent adrenal mass: update in diagnosis and management Endocr Rev 25 2004 309 340
5. F. Mantero, M. Terzolo, and G. Arnaldi et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology J Clin Endocrinol Metab 85 2000 637 644
6. M.A. Long, and J.E. Husband Features of unusual metastases from prostate cancer Br J Radiol 72 1999 933 941
7. L. Bubendorf, A. Schopfer, and U. Wagner et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients Hum Pathol 31 2000 578 583
8. A.H. Vinjamoori, J.P. Jagannathan, and A.B. Shinagare et al. Atypical metastases from prostate cancer: 10-year experience at a single institution AJR Am J Roentgenol 199 2012 367 372
9. C.J. Pezaro, A. Omlin, and D. Lorente et al. Visceral Disease in Castration-resistant Prostate Cancer Eur Urol 65 2014 270 273
10. E.A. Eisenhauer, P. Therasse, and J. Bogaerts et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
11. G. Attard, A.H. Reid, and T.A. Yap et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven J Clin Oncol 26 2008 4563 4571
12. O. Goldsmith, D.H. Solomon, and R. Horton Hypogonadism and mineralocorticoid excess. The 17-hydroxylase deficiency syndrome N Engl J Med 277 1967 673 677
13. T. Yanase, E.R. Simpson, and M.R. Waterman 17 alpha-hydroxylase/17,20- lyase deficiency: from clinical investigation to molecular definition Endocr Rev 12 1991 91 108
14. E.G. Perez, L.G. del Rincon, and O.T. Loza et al. P450C17 (CYP17) deficiency in native Mexican patient with a novel CYP17A1 mutation Endocr Pract 17 2011 99 103
15. R.J. Auchus The genetics, pathophysiology, and management of human deficiencies of P450c17 Endocrinol Metab Clin North Am 30 2001 101 119 vii
16. A. Omlin, C. Pezaro, and D. Mukherji et al. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms Eur Urol 64 2013 300 306
17. S. Doctor, C.K. Tsao, and J.H. Godbold et al. Evolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011 J Clin Oncol 2013 31 (abstract 5015)